Holen Sie sich die Stockscreener-App
208.23
1.91%
-3.25
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$211.48
Offen:
$211.48
24-Stunden-Volumen:
56,662
Relative Volume:
0.27
Marktkapitalisierung:
$4.16B
Einnahmen:
$268.09M
Nettoeinkommen (Verlust:
$124.45M
KGV:
35.69
EPS:
5.8347
Netto-Cashflow:
$38.05M
1W Leistung:
+2.74%
1M Leistung:
+12.84%
6M Leistung:
+25.15%
1J Leistung:
+96.40%
1-Tages-Spanne:
$204.90
$214.80
1-Wochen-Bereich:
$196.17
$227.92
52-Wochen-Spanne:
$93.58
$227.92
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
208.50 | 4.22B | 268.09M | 124.45M | 38.05M | 5.8347 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.98 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.96 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
701.94 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.08 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.94 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Citigroup | Buy |
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
How a broad sell-off rattled top 3% breakout stock Ligand Pharma - MSN
LIGAND PHARMACEUTICALS INCORPORATED (LGND) - MSN
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After A 105% One-Year Surge? - simplywall.st
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Up 6.9%What's Next? - MarketBeat
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says - Yahoo! Finance Canada
BofA Securities Initiates Ligand Pharmaceuticals at Buy With $244 Price Target - marketscreener.com
Bofa Global Research announced that it has initiated coverage of Ligand Pharmaceuticals Inc. for the first time, assigning it a "Buy" rating. - Bitget
Ligand stock gains new Buy from BofA (LGND:NASDAQ) - Seeking Alpha
Ligand Pharmaceuticals (LCTX) raises ATM ceiling to $60M with B. Riley - Stock Titan
LGND: B of A Securities Initiates Coverage with Buy Rating and $244 PT | LGND Stock News - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Analysts at Bank of America - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Ligand Pharmaceuticals stock hits 52-week high at $213.02 By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 1-Year HighStill a Buy? - MarketBeat
How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth - Yahoo Finance
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Ligand Pharmaceuticals CLO Reardon sells $1m in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells $2,762,856.09 in Stock - MarketBeat
Andrew Reardon Sells 5,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
Ligand Pharmaceuticals director Sabba sells $409k in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $409,851.00 in Stock - MarketBeat
Ligand Pharmaceuticals director Sabba sells $409k in shares By Investing.com - Investing.com Canada
Citigroup Inc. Trims Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals director sells $93k in stock - Investing.com India
Ligand Pharmaceuticals director sells $93k in stock By Investing.com - Investing.com Nigeria
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Ligand Pharma (LGND) Earnings Call Transcript - AOL.com
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 467 Shares of Stock - MarketBeat
Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity ShelfWhat's Changed - simplywall.st
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand to Participate in March Investor Conferences - The Manila Times
Ligand plans three March investor appearances in Miami, Dana Point, NYC - Stock Titan
Ligand Pharmaceuticals (LGND): Investor Outlook With 20.74% Potential Upside - DirectorsTalk Interviews
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? - Yahoo Finance
Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts - Sahm
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
LGND Should I Buy - Intellectia AI
Decoding Ligand Pharmaceuticals Inc (LGND): A Strategic SWOT Ins - GuruFocus
Oppenheimer Raises Price Target for LGND, Maintains Outperform R - GuruFocus
Ligand Pharmaceuticals Files For Mixed Shelf Offering - TradingView
Ligand Pharmaceuticals (NASDAQ: LGND) files S-3 for $100M ATM offering with Leerink - Stock Titan
LIGAND PHARMACEUTICALS INC SEC 10-K Report - TradingView
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating - marketscreener.com
Vanguard Group Inc. Has $367.79 Million Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Assessing Ligand Pharmaceuticals (LGND) Valuation After Strong One Year Returns And Elevated P/E Ratio - simplywall.st
Oppenheimer raises Ligand Pharma stock price target on royalty outlook By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Announces Quarterly Earnings Results, Beats Expectations By $0.56 EPS - MarketBeat
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):